DE602004029678D1 - Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai - Google Patents
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnaiInfo
- Publication number
- DE602004029678D1 DE602004029678D1 DE602004029678T DE602004029678T DE602004029678D1 DE 602004029678 D1 DE602004029678 D1 DE 602004029678D1 DE 602004029678 T DE602004029678 T DE 602004029678T DE 602004029678 T DE602004029678 T DE 602004029678T DE 602004029678 D1 DE602004029678 D1 DE 602004029678D1
- Authority
- DE
- Germany
- Prior art keywords
- sirna duplex
- antisense strand
- strand
- fnai
- specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XPAGMQMUQHZWID-UHFFFAOYSA-N 3',6'-dihydroxy-6-(2-imidazol-1-yl-2-oxoethyl)spiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2CC(=O)N1C=CN=C1 XPAGMQMUQHZWID-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 5
- 230000000692 anti-sense effect Effects 0.000 abstract 5
- 108091081021 Sense strand Proteins 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/331—Universal or degenerate base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Electrotherapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47533103P | 2003-06-02 | 2003-06-02 | |
| US50792803P | 2003-09-30 | 2003-09-30 | |
| US57526804P | 2004-05-28 | 2004-05-28 | |
| PCT/US2004/017256 WO2005001043A2 (en) | 2003-06-02 | 2004-06-02 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004029678D1 true DE602004029678D1 (de) | 2010-12-02 |
Family
ID=33556382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004029678T Expired - Lifetime DE602004029678D1 (de) | 2003-06-02 | 2004-06-02 | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8309704B2 (de) |
| EP (2) | EP2314692B1 (de) |
| AT (1) | ATE485394T1 (de) |
| AU (2) | AU2004252442B2 (de) |
| CA (1) | CA2527958C (de) |
| DE (1) | DE602004029678D1 (de) |
| ES (2) | ES2864206T3 (de) |
| WO (1) | WO2005001043A2 (de) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| SI1504126T1 (sl) | 2002-05-03 | 2014-08-29 | Duke University Office Of Science And Technology | Postopek regulacije izraĹľanja genov |
| US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
| EP2305812A3 (de) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Funktionale und hyperfunktionale siRNA |
| US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
| US7592442B2 (en) | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
| US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
| US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
| US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| AU2003298718A1 (en) * | 2002-11-22 | 2004-06-18 | University Of Massachusetts | Modulation of hiv replication by rna interference |
| EP1605978B1 (de) | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutische zusammensetzungen |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| WO2005001043A2 (en) | 2003-06-02 | 2005-01-06 | University Of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| ES2712695T3 (es) * | 2003-06-02 | 2019-05-14 | Univ Massachusetts | Métodos y composiciones para controlar la eficacia de la silenciación del ARN |
| WO2005017154A1 (ja) * | 2003-08-18 | 2005-02-24 | Japan Health Sciences Foundation | 改良されたｓｉＲＮＡ分子およびこれを用いた遺伝子発現の抑制法 |
| US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| DK2821085T3 (da) | 2003-09-12 | 2020-08-03 | Univ Massachusetts | Rna-interferens til behandling af "gain-of-function"-forstyrrelser |
| US20060218673A9 (en) | 2003-10-09 | 2006-09-28 | E.I. Du Pont De Nemours And Company | Gene silencing |
| CA2546669C (en) | 2003-11-26 | 2021-08-03 | University Of Massachusetts | Sequence-specific inhibition of small rna function |
| US20060134787A1 (en) | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
| WO2005079532A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Massachusetts | Methods and compositions for enhancing risc activity in vitro and in vivo |
| US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US7605250B2 (en) * | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
| JP5435864B2 (ja) | 2004-05-28 | 2014-03-05 | アシュラジェン インコーポレイテッド | マイクロｒｎａに関与する方法および組成物 |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| CA2569419A1 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| CA2583690C (en) * | 2004-10-12 | 2016-04-05 | The Rockefeller University | Microrna constructs for the suppression of the expression of targeted genes or the down regulation of targeted genes and methods therefore |
| EP2284265B1 (de) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind |
| US20100069620A1 (en) * | 2004-12-02 | 2010-03-18 | Rxi Pharmaceuticals Corp. | Novel compositions of chemically modified small interfering rna |
| JP2009504782A (ja) | 2005-08-18 | 2009-02-05 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 神経疾患を治療するための方法および組成物 |
| US20090018097A1 (en) * | 2005-09-02 | 2009-01-15 | Mdrna, Inc | Modification of double-stranded ribonucleic acid molecules |
| FR2890859B1 (fr) | 2005-09-21 | 2012-12-21 | Oreal | Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase |
| AU2007212700A1 (en) * | 2006-01-26 | 2007-08-16 | University Of Massachusetts | RNA interference agents for therapeutic use |
| WO2008104978A2 (en) * | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
| WO2008143786A1 (en) * | 2007-05-14 | 2008-11-27 | The Rockefeller University | Production of artificial micrornas using synthetic microrna precursors |
| WO2009036332A1 (en) | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| CA2704737A1 (en) * | 2007-09-18 | 2009-09-03 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
| US20100280097A1 (en) * | 2007-09-18 | 2010-11-04 | Intradigm Corporation | Compositions comprising hif-1 alpha sirna and methods of use thereof |
| CN101849008A (zh) | 2007-09-19 | 2010-09-29 | 应用生物系统有限公司 | 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式 |
| US8614309B2 (en) * | 2007-10-03 | 2013-12-24 | Quark Pharmaceuticals, Inc. | Double-stranded RNA directed to CASP2 and methods of use thereof |
| WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009074990A2 (en) * | 2007-12-12 | 2009-06-18 | Quark Pharmaceuticals, Inc. | Rtp801l sirna compounds and methods of use thereof |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
| WO2009102427A2 (en) | 2008-02-11 | 2009-08-20 | Rxi Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
| US20110028531A1 (en) * | 2008-03-20 | 2011-02-03 | Elena Feinstein | Novel sirna compounds for inhibiting rtp801 |
| US8278287B2 (en) * | 2008-04-15 | 2012-10-02 | Quark Pharmaceuticals Inc. | siRNA compounds for inhibiting NRF2 |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| EP2293800B1 (de) * | 2008-06-06 | 2016-10-05 | Quark Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung von ohrerkrankungen |
| WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
| JP2011528910A (ja) * | 2008-07-25 | 2011-12-01 | アルニラム ファーマスーティカルズ インコーポレイテッド | センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進 |
| CA3027780A1 (en) | 2008-09-22 | 2010-03-25 | Phio Pharmaceuticals Corp. | Reduced size self-delivering rnai compounds |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
| US8901097B2 (en) | 2009-11-08 | 2014-12-02 | Quark Pharmaceuticals, Inc. | Methods for delivery of siRNA to the spinal cord and therapies arising therefrom |
| NZ599237A (en) | 2009-11-26 | 2014-03-28 | Quark Pharmaceuticals Inc | Sirna compounds comprising terminal substitutions |
| EP3012324A3 (de) | 2009-12-09 | 2016-07-06 | Nitto Denko Corporation | Modulation der hsp47-expression |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| WO2011115810A2 (en) * | 2010-03-16 | 2011-09-22 | Massachusetts Institute Of Technology | Isoform-specific rnai based on codon redundancy/degeneracy |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| KR102453078B1 (ko) | 2010-03-24 | 2022-10-11 | 피오 파마슈티칼스 코프. | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| SG186438A1 (en) * | 2010-06-24 | 2013-01-30 | Quark Pharmaceuticals Inc | Double stranded rna compounds to rhoa and use thereof |
| SG190412A1 (en) | 2010-12-06 | 2013-06-28 | Quark Pharmaceuticals Inc | Double stranded oligonucleotide compounds comprising threose modifications |
| US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
| US9777277B2 (en) | 2013-05-31 | 2017-10-03 | Brandeis University | Organic small hairpin RNAs |
| CN105452465B (zh) | 2013-07-31 | 2019-06-21 | 奇比艾企业有限公司 | 鞘脂-聚烷基胺-寡核苷酸化合物 |
| WO2015015498A1 (en) | 2013-07-31 | 2015-02-05 | Qbi Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| KR101670254B1 (ko) * | 2014-07-09 | 2016-10-28 | 서울대학교산학협력단 | 목적 유전자의 발현 억제 특이성이 증가된 siRNA 분자 |
| KR102689262B1 (ko) | 2014-09-05 | 2024-07-30 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| EP3218484A4 (de) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als) |
| PL3277815T3 (pl) | 2015-04-03 | 2022-03-21 | University Of Massachusetts | Związki oligonukleotydowe do leczenia stanu przedrzucawkowego i innych zaburzeń angiogennych |
| LT3277814T (lt) | 2015-04-03 | 2020-10-26 | University Of Massachusetts | Oligonukleotidų junginiai, skirti nukreipimui į hantingtino mrnr |
| EP3277811B1 (de) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Vollständig stabilisierte asymmetrische sirna |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| EP3319614B1 (de) | 2015-07-06 | 2020-12-23 | Phio Pharmaceuticals Corp. | Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| EP3408391A4 (de) | 2016-01-31 | 2019-08-28 | University of Massachusetts | Verzweigte oligonukleotide |
| MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| MA45349A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques egfr et leurs utilisations |
| MA45470A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
| IL297576B2 (en) * | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Preparations and methods for treating Huntington's disease |
| EP3496758A4 (de) | 2016-08-12 | 2020-11-11 | University of Massachusetts | Konjugierte oligonukleotide |
| US10443055B2 (en) | 2016-12-22 | 2019-10-15 | Beth Israel Deaconess Medical Center | Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| EP3642341A4 (de) | 2017-06-23 | 2021-06-16 | University Of Massachusetts | Zweiendige selbstfreisetzende sirna und verwandte verfahren |
| TWI804518B (zh) | 2017-10-16 | 2023-06-11 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| KR102443358B1 (ko) | 2017-12-06 | 2022-09-14 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
| AU2019316640A1 (en) | 2018-08-10 | 2021-03-18 | University Of Massachusetts | Modified oligonucleotides targeting SNPs |
| JP2021533804A (ja) | 2018-08-23 | 2021-12-09 | ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts | Ｏ−メチルリッチ完全安定化オリゴヌクレオチド |
| CN114072501A (zh) | 2019-05-06 | 2022-02-18 | 马萨诸塞大学 | 抗c9orf72寡核苷酸及相关方法 |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| CA3162845A1 (en) | 2019-12-23 | 2021-07-01 | Anastasia Khvorova | Oligonucleotides for tissue specific gene expression modulation |
| JP2023537798A (ja) | 2020-03-19 | 2023-09-06 | アビディティー バイオサイエンシーズ，インク． | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 |
| CN115698291A (zh) | 2020-05-28 | 2023-02-03 | 马萨诸塞大学 | 用于SARS-CoV-2调节的寡核苷酸 |
| EP4359539A1 (de) | 2021-06-23 | 2024-05-01 | University Of Massachusetts | Optimierte anti-flt1-oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| ATE68013T1 (de) | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| US5252726A (en) | 1987-09-04 | 1993-10-12 | Novo Nordisk A/S | Promoters for use in aspergillus |
| JP3015383B2 (ja) | 1987-09-11 | 2000-03-06 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 形質導入した線維芽およびそれらの使用 |
| DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Hughes Howard Med Inst | Genetische modifizierung von endothelialen zellen. |
| WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5070020A (en) | 1988-05-09 | 1991-12-03 | Eli Lilly And Company | Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
| EP0452457B1 (de) | 1989-11-03 | 1997-08-20 | Vanderbilt University | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
| US6946587B1 (en) | 1990-01-22 | 2005-09-20 | Dekalb Genetics Corporation | Method for preparing fertile transgenic corn plants |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| ES2115662T3 (es) | 1990-10-31 | 1998-07-01 | Cell Genesys Inc | Modificacion genetica de celulas endoteliales. |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20040002153A1 (en) | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| US20020173478A1 (en) † | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| HU230458B1 (hu) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
| WO2003035869A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens |
| WO2003006477A1 (en) | 2001-07-12 | 2003-01-23 | University Of Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US7820632B2 (en) | 2002-02-14 | 2010-10-26 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
| SI1504126T1 (sl) | 2002-05-03 | 2014-08-29 | Duke University Office Of Science And Technology | Postopek regulacije izraĹľanja genov |
| CA2489174C (en) | 2002-07-10 | 2013-02-05 | Thomas Tuschl | Rna-interference by single-stranded rna molecules |
| ES2389024T3 (es) | 2002-08-05 | 2012-10-22 | Silence Therapeutics Aktiengesellschaft | Moléculas de RNA interferentes de extremos romos |
| ATE350473T2 (de) | 2002-08-05 | 2007-01-15 | Atugen Ag | Weitere neue formen von interferierende rns moleküle |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| EP1546344A4 (de) | 2002-09-18 | 2007-10-03 | Isis Pharmaceuticals Inc | Effiziente produktion von ziel-rnas mittels einzel- und doppelsträngiger oligomerverbindungen |
| CA2500224C (en) | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| EP1567539B1 (de) | 2002-11-04 | 2009-09-23 | University of Massachusetts | Allelspezifische rna-interferenz |
| US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
| EP2305812A3 (de) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Funktionale und hyperfunktionale siRNA |
| US20040214198A1 (en) | 2002-11-15 | 2004-10-28 | University Of Massachusetts | Allele-targeted RNA interference |
| US20040248299A1 (en) | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
| US20040224328A1 (en) | 2003-01-15 | 2004-11-11 | Hans Prydz | siRNA screening method |
| WO2004063375A1 (en) | 2003-01-15 | 2004-07-29 | Hans Prydz | OPTIMIZING siRNA BY RNAi ANTISENSE |
| EP2314687B1 (de) | 2003-01-17 | 2017-12-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung |
| WO2004064737A2 (en) | 2003-01-17 | 2004-08-05 | Alnylam Pharmaceuticals | Therapeutics compositions |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| EP1605978B1 (de) † | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutische zusammensetzungen |
| WO2005001043A2 (en) | 2003-06-02 | 2005-01-06 | University Of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| ES2712695T3 (es) | 2003-06-02 | 2019-05-14 | Univ Massachusetts | Métodos y composiciones para controlar la eficacia de la silenciación del ARN |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| CA2546669C (en) | 2003-11-26 | 2021-08-03 | University Of Massachusetts | Sequence-specific inhibition of small rna function |
| WO2005062937A2 (en) | 2003-12-22 | 2005-07-14 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna |
| US20060134787A1 (en) | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
| US20050227940A1 (en) | 2004-01-23 | 2005-10-13 | City Of Hope | Amplifying interfering RNA (RNAi) expression and effects |
| US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| US20060069050A1 (en) | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
| WO2005079532A2 (en) | 2004-02-17 | 2005-09-01 | University Of Massachusetts | Methods and compositions for enhancing risc activity in vitro and in vivo |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| US20060178334A1 (en) | 2005-02-04 | 2006-08-10 | City Of Hope | Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon |
-
2004
- 2004-06-02 WO PCT/US2004/017256 patent/WO2005001043A2/en active Application Filing
- 2004-06-02 AT AT04753972T patent/ATE485394T1/de not_active IP Right Cessation
- 2004-06-02 EP EP10181632.0A patent/EP2314692B1/de not_active Expired - Lifetime
- 2004-06-02 ES ES10181632T patent/ES2864206T3/es not_active Expired - Lifetime
- 2004-06-02 EP EP04753972.1A patent/EP1633890B2/de not_active Expired - Lifetime
- 2004-06-02 ES ES04753972T patent/ES2357116T5/es not_active Expired - Lifetime
- 2004-06-02 AU AU2004252442A patent/AU2004252442B2/en not_active Expired
- 2004-06-02 CA CA2527958A patent/CA2527958C/en not_active Expired - Lifetime
- 2004-06-02 US US10/859,321 patent/US8309704B2/en active Active
- 2004-06-02 DE DE602004029678T patent/DE602004029678D1/de not_active Expired - Lifetime
-
2010
- 2010-07-07 AU AU2010202861A patent/AU2010202861B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES2357116T5 (es) | 2021-09-03 |
| EP1633890A2 (de) | 2006-03-15 |
| AU2004252442B2 (en) | 2010-04-08 |
| ATE485394T1 (de) | 2010-11-15 |
| US20050181382A1 (en) | 2005-08-18 |
| EP2314692A3 (de) | 2011-08-03 |
| CA2527958A1 (en) | 2005-01-06 |
| WO2005001043A3 (en) | 2005-12-29 |
| EP1633890A4 (de) | 2006-11-29 |
| AU2010202861B2 (en) | 2013-05-23 |
| US8309704B2 (en) | 2012-11-13 |
| EP2314692B1 (de) | 2021-02-24 |
| CA2527958C (en) | 2014-04-08 |
| ES2357116T3 (es) | 2011-04-18 |
| EP2314692A2 (de) | 2011-04-27 |
| AU2004252442A1 (en) | 2005-01-06 |
| AU2010202861A1 (en) | 2010-08-05 |
| WO2005001043A2 (en) | 2005-01-06 |
| ES2864206T3 (es) | 2021-10-13 |
| EP1633890B2 (de) | 2020-11-18 |
| EP1633890B1 (de) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004029678D1 (de) | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai | |
| DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
| ATE513843T1 (de) | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna | |
| EA200500019A1 (ru) | Ксиланазы, кодирующие их нуклеиновые кислоты и способы их получения и применения | |
| DE60329277D1 (de) | Oligonukleotidzusammensetzungen mit verbesserter effizienz | |
| ZA200209096B (en) | Use of particular aminosilicones as a post-treatment of processes for colouring keratin fibres with direct dyes or with oxidation dyes. | |
| WO2005121370A3 (en) | Oligomeric compounds that facilitate risc loading | |
| WO2003011887A3 (en) | Antisense modulation of apolipoprotein b expression | |
| HRP20130750T1 (hr) | Postupak identifikacije molekula za vezanje koje mogu neutralizirati virus bjesnoä†e | |
| DK1250455T3 (da) | Antisense-inhibering af PTP1B-ekspression | |
| DE50109303D1 (de) | Polysiloxanpolymere, verfahren zu ihrer herstellung und ihre verwendung | |
| EP1248794A4 (de) | Antisens-modulierung der smad7 expression | |
| DE60105732D1 (de) | Verfahren zur Herstellung von 3-l-Menthoxypropan-1,2-diol | |
| DK1930439T3 (da) | Neurotrofe faktorer | |
| WO2005049832A3 (en) | FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE | |
| WO2003046132A3 (en) | Antisense modulation of myd88 expression | |
| WO2003057843A3 (en) | Methods and materials for modulating trpc4 | |
| WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
| WO2002095053A3 (en) | Antisense modulation of src-c expression | |
| EP1648910A4 (de) | Antisense-modulation der expression von stearoyl coa desaturase | |
| WO2003052062A3 (en) | Antisense modulation of cd36l1 expression | |
| WO2002036810A3 (en) | Antisense modulation of talin expression | |
| ATE361755T1 (de) | Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen | |
| DE60235867D1 (de) | Verwendung von speziellen Aminosilikonen zur Vor- oder Nachbehandlung in der Entfärbung von Keratinfasern | |
| WO2003057847A3 (en) | METHODS AND MATERIALS FOR MODULATING ENaC-BETA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent |